What were the most commonly reported adverse reactions to omalizumab in allergic asthma trials involving patients aged 12 years and older?

In allergic asthma trials involving patients aged 12 years and older, the most commonly reported adverse reactions to omalizumab were headaches and injection-site reactions, including pain, swelling, erythema and pruritus.